The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Open accessAbstract
BACKGROUND.: Low voriconazole levels have been associated with a higher failure rate in patients with confirmed fungal infections. METHODS.: Steady‐state plasma trough voriconazole levels were measured after at least 5 days of therapy in 87 patients with hematologic malignancies on 201 separate occasions (1–5 levels per patient; median, 2). Most patients (90%) had undergone allogeneic hematopoietic stem cell transplantation. The daily voriconazole dose, administered in 2 divided doses, was 200 mg (n = 4), 400 mg (n = 151), 500 mg (n = 20), 600 mg (n = 18), and 800 mg (n = 8); corresponding to 2.0–16.3 (median, 5.4) mg/kg. Plasma voriconazole levels were 0–12.5 μg/mL (median, 1.2). Voriconazole was undetectable (<0.2 μg/mL) in 15%. RESULTS.: The correlation between dose and levels was weak (r = 0.14; P = .045). The median absolute daily drug dose (400 mg) was identical in groups of patients with levels of 0, 0.2 to 0.5, >0.5 to 2.0, >2.0 to 5.0, and >5.0. Whereas the daily drug dose in mg/kg was significantly higher when the levels were >5.0 μg/mL, there was no consistent relation between dose and level below that threshold. In adult patients getting standard doses of voriconazole orally, the drug levels are highly variable. Based on limited available data, between a quarter and two‐thirds of these levels could potentially be associated with a lower likelihood of response or a higher likelihood of failure. CONCLUSIONS.: Future voriconazole studies should incorporate prospective therapeutic drug monitoring and consideration should be given to checking levels in patients receiving the drug for confirmed, life‐threatening fungal infections. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231
Cited by
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Verweij, P. E., Rijnders, B. J. A., Brüggemann, R. J. M., Azoulay, E., Bassetti, M., Blot, S., Calandra, T., Clancy, C. J., Cornely, O. A., Chiller, T., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06091-6 · Cited by 459
Metadata
- Authors
- Trifilio, S., Pennick, G., Pi, J., Zook, J., Golf, M., Kaniecki, K., Singhal, S., Williams, S., Winter, J., Tallman, M., Gordon, L., Frankfurt, O., Evens, A., & Mehta, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-03-09
- Volume
- 109
- Issue
- 8
- Pages
- 1532-1535
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2090225402
- Cited by
- 199
- References
- 2
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. https://app.cochat.ai/papers/10.1002/cncr.22568
- The paper
- Trifilio, S., Pennick, G., Pi, J., Zook, J., Golf, M., Kaniecki, K., Singhal, S., Williams, S., Winter, J., Tallman, M., Gordon, L., Frankfurt, O., Evens, A., & Mehta, J. (2007). Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. https://doi.org/10.1002/cncr.22568
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.